In NCI-H460, which is a p53 wild-type lung cancer cell line model, XR-2 suppressed NCI-H460 tumor progression effectively, and XR-2 did not delay the weight gain of mice that received the therapeutic dose. This evidence concerns the gene TP53 and lung cancer.